Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Twentyeight-Seven’s bet on RNA-binding proteins

Twentyeight-Seven is capitalizing on the emerging biology of RNA-binding proteins by targeting their interactions with non-coding RNAs

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins.

Launched last September, the company is using an $82.8 million series A round backed by a syndicate that includes MPM Capital, Novartis Venture Fund and Sofinnova Partners to advance its lead cancer program and extend its platform to similar targets in other indications, including inflammatory diseases.

By modulating gene

Read the full 703 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers